Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Columbia University
Emory University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: February 23, 2006
Last updated: September 26, 2016
Last verified: September 2016